The FDA has revoked its emergency use authorization for hydroxychloroquine as a treatment for COVID-19 hospital patients, determining that the controversial drug was “unlikely to be effective in treating COVID-19.”

The rule eliminates provisions of a 2016 rule from the Obama administration that attempted to protect trans patients from discrimination.

HHS is distributing another $35 billion from the CARES Act designated for healthcare providers responding to the crisis. The CARES Act allocated $175 billion in relief funds to hospitals and healthcare providers, especially those majorly affected by the pandemic.

HHS has announced new laboratory data reporting guidance for COVID-19 testing, expanding requirements for laboratories to report demographic details that can help improve the public response.

CMS is increasing enforcement, including civil penalties, against nursing homes with persistent infection control violations for COVID-19. 

President Trump has stated he wants to terminate the United States’ relationship with the World Health Organization.

More than 1,750 standalone Medicare Part D prescription drug plans and MA plans have applied to offer insulin at a maximum $35 copay for a month’s supply of the drug for the 2021 plan year, CMS announced.

CMS has finalized a rule to implement a series of proposals issued earlier this year impacting Medicare Advantage plans and Medicare Part D plan sponsors. The rules were rushed into effect to get them out before the contract year 2021 bid deadline in June.

CMS has issued a plan to reopen the nation’s nursing homes with a new guidance for state and local officials.

CVS Health has stated it will return $43 million in funding it received for COVID-19 relief.

Civica Rx has teamed up with the U.S. government to aid in the COVID-19 response.

As analyzed by the Kaiser Family Foundation, the outlook for job-based insurance under some post-COVID scenarios is unsurprisingly bleak.